Pfizer has an excellent heritage in cardiovascular medicine. Our portfolio includes treatments to prevent stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), treatments of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT & PE in adults. Pfizer also has a focus on rare cardiovascular disease including Transthyretin Amyloidosis (ATTR-CM)


PP-GIP-IRL-0327 Date of Preparation November 2021